Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects.

Blood levels of C-reactive protein (CRP), a marker of inflammation, are related to cardiovascular disease risk. To determine cross-sectional correlates in the elderly, we measured CRP in 400 men and women older than 65 years and free of clinical cardiovascular disease at baseline as part of the Cardiovascular Health Study. Only 2% of the values were greater than 10 mg/L, the cut-point usually used to identify inflammation. CRP levels appeared tightly regulated, since there were strong bivariate correlations between CRP and the following: inflammation-sensitive proteins such as fibrinogen (r = .52); measures of fibrinolysis such as plasmin-antiplasmin complex (r = .23); pack-years of smoking (r = .30); and body mass index (r = .24; all P values < or = .001). The association with pack-years was independent of the length of time since cessation of smoking. CRP levels were also associated with coagulation factors VIIc, IXc, and Xc; HDL cholesterol (negative) and triglyceride; diabetes status; diuretic use; ECG abnormalities; and level of exercise. Because of effect modification, two multiple linear regression prediction models were developed for CRP, one each for never smokers and ever smokers. An a priori physiologic model was used to guide these analyses, which disallowed the use of other inflammation-sensitive variables such as fibrinogen. In never smokers, the independent predictors were body mass index (+), diabetes status (+), plasmin-antiplasmin complex (+), and the presence of ECG abnormalities (+); this model predicted 15% of the CRP population variance. In ever smokers, the predictors were body mass index (+), plasmin-antiplasmin complex (+), pack-years of smoking (+), HDL cholesterol (-), and ankle-arm blood pressure index (-); this model predicted 42% of the population variance. We conclude that levels of CRP in the healthy elderly are tightly regulated and reflect lifetime exposure to smoking as well as level of obesity, ongoing level of fibrinolysis, diabetes status, and level of subclinical atherothrombotic disease. Moreover, exposure to smoking affects the relation of CRP to these other factors.

[1]  L H Kuller,et al.  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[2]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.

[3]  L. Kuller,et al.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.

[4]  L. Kuller,et al.  Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[5]  J. Harvey-Berino,et al.  Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. , 1996, The American journal of clinical nutrition.

[6]  P. Savage,et al.  Association of Fibrinogen and Coagulation Factors Vll and VIII with Cardiovascular Risk Factors in the Elderly The Cardiovascular Health Study , 1996 .

[7]  C. Alpers,et al.  Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. , 1996, Circulation.

[8]  T. Ueno,et al.  Increased soluble form of P-selectin in patients with unstable angina. , 1995, Circulation.

[9]  P. Savage,et al.  Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health Study. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[10]  P. Savage,et al.  Coronary heart disease prevalence and its relation to risk factors in American Indians. The Strong Heart Study. , 1995, American journal of epidemiology.

[11]  A. Blann,et al.  von Willebrand Factor, Soluble P-Selectin, Tissue Plasminogen Activator and Plasminogen Activator Inhibitor in Atherosclerosis , 1995, Thrombosis and Haemostasis.

[12]  S. Thompson,et al.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.

[13]  M. Cushman,et al.  Laboratory methods and quality assurance in the Cardiovascular Health Study. , 1995, Clinical chemistry.

[14]  R. Tracy,et al.  The measurement of fibrinogen in population-based research. Studies on instrumentation and methodology. , 1994, Archives of pathology & laboratory medicine.

[15]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[16]  A. Blann,et al.  Circulating Endothelial Cell/Leukocyte Adhesion Molecules in Atherosclerosis , 1994, Thrombosis and Haemostasis.

[17]  J. Gardin,et al.  Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. , 1994, American journal of epidemiology.

[18]  V. Fuster,et al.  Atherogenesis and inflammation. , 1993, European heart journal.

[19]  J. Polak,et al.  Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. , 1993, Circulation.

[20]  M. Entman,et al.  Inflammation in Acute Coronary Syndromes , 1993, Circulation.

[21]  G. Vercellotti,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor , 1993 .

[22]  L. Fried,et al.  Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. , 1993, Annals of epidemiology.

[23]  C. Fraser,et al.  Biological Variation of Acute Phase Proteins , 1993, Annals of clinical biochemistry.

[24]  E. Meilahn,et al.  Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies. , 1993, Archives of pathology & laboratory medicine.

[25]  B. Klein,et al.  C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. , 1992, Arthritis and rheumatism.

[26]  B. Psaty,et al.  Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group. , 1992, The American journal of cardiology.

[27]  H. S. Klopfenstein,et al.  Echocardiographic design of a multicenter investigation of free-living elderly subjects: the Cardiovascular Health Study. , 1992, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[28]  K. Mann,et al.  Studies on the measurement of protein S in plasma. , 1991, Clinical chemistry.

[29]  B M Psaty,et al.  Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. , 1991, Stroke.

[30]  M. Nyska,et al.  Acute Phase Protein, Serum Amyloid A, Inhibits IL‐1‐ and TNF‐Induced Fever and Hypothalamic PGE2 in Mice , 1991, Scandinavian journal of immunology.

[31]  G. Fuller,et al.  The putative role of fibrin fragments in the biosynthesis of fibrinogen by hepatoma cells. , 1991, Biochemical and biophysical research communications.

[32]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[33]  P. Declerck,et al.  Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. , 1990, Thrombosis research.

[34]  A. Marcus,et al.  Stratton lecture 1989. Thrombosis and inflammation as multicellular processes: pathophysiologic significance of transcellular metabolism. , 1990, Blood.

[35]  N. Ku,et al.  Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-beta. , 1990, Journal of immunology.

[36]  K. Mann,et al.  Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. , 1990, Blood.

[37]  I. Kushner,et al.  C-reactive protein and the acute-phase response. , 1990, Hospital practice.

[38]  P. Hass,et al.  A monoclonal-antibody-based enzyme-linked immunosorbent assay of lipoprotein(a). , 1990, Clinical chemistry.

[39]  P. Declerck,et al.  Measurement of different forms of plasminogen activator inhibitor 1(PAI-1) using various monoclonal antibody-based enzyme-linked immunosorbent assays , 1990 .

[40]  R. Macwalter,et al.  Biological variability of 26 clinical chemistry analytes in elderly people. , 1989, Clinical chemistry.

[41]  S. Deodhar,et al.  C-reactive protein: the best laboratory indicator available for monitoring disease activity. , 1989, Cleveland Clinic journal of medicine.

[42]  C G Fraser,et al.  Generation and application of data on biological variation in clinical chemistry. , 1989, Critical reviews in clinical laboratory sciences.

[43]  K. Mann,et al.  A monoclonal-antibody-based radioimmunoassay for measurement of protein C in plasma. , 1988, Clinical chemistry.

[44]  R. Cotran,et al.  The pathogenesis of atherosclerosis: atherogenesis and inflammation. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[45]  M. Alessi,et al.  Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. , 1988, Blood.

[46]  P. Holvoet,et al.  An Enzyme-Linked Immunosorbent Assay (ELISA) for the Measurement of Plasmin-α2-Antiplasmin Complex in Human Plasma - Application to the Detection of In Vivo Activation of the Fibrinolytic System , 1986, Thrombosis and Haemostasis.

[47]  I. Das,et al.  Raised C-reactive protein levels in serum from smokers. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[48]  D. Collen,et al.  Assay of Human Tissue-Type Plasminogen Activator (t-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies to t-PA , 1985, Thrombosis and Haemostasis.

[49]  A. J. Valente,et al.  Atherosclerosis as an Inflammatory Process , 1985, Annals of the New York Academy of Sciences.

[50]  N. Tietz Clinical guide to laboratory tests , 1983 .

[51]  I. Kushner,et al.  SERUM C‐REACTIVE PROTEIN LEVELS IN DISEASE * , 1982, Annals of the New York Academy of Sciences.

[52]  D. Ritchie,et al.  Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[53]  C. Mold,et al.  C-reactive protein and the acute phase response. , 1982, Advances in internal medicine.

[54]  D. Karp,et al.  Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. , 1978, The Journal of clinical investigation.

[55]  E. Simonson,et al.  The Electrocardiogram in Population Studies: A Classification System , 1960, Circulation.